Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,348
datasets available to search
ShareScore release 0.9.0
Dataset results
6,348 results for “Hepatitis”
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a
ClinicalTrials.gov study NCT02939989. IPD Sharing: YES. Countries: 12. Publications: 1.
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
ClinicalTrials.gov study NCT04042740. IPD Sharing: YES. Countries: 2. Publications: 1.
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
ClinicalTrials.gov study NCT00100659. IPD Sharing: YES. Countries: 1. Publications: 9.
Data from: Single cell transcriptomics shows dose-dependent disruption of hepatic zonation by TCDD in mice
Open the record for dataset details and reuse information.
Reducing Hepatitis C diagnostic disparities with a point of care assay for HCV antigen detection
Open the record for dataset details and reuse information.
Gestational Cd exposure in the CD-1 mouse induces sex-specific hepatic insulin insensitivity, obesity and metabolic syndrome in adult female offspring
Open the record for dataset details and reuse information.
Data from: Gut microbiome critically impacts PCB-induced changes in metabolic fingerprints and the hepatic transcriptome in mice
<p class="western"><span><span><span>Polychlorinated biphenyls (PCBs) are ubiquitously detected in the environment and have been linked to metabolic diseases. The liver serves as a central hub for the metabolism of xenobiotics and endogenous metabolites. Gut dysbiosis is recognized as a critical regulator of disease susceptibility, however, little is known regarding how PCBs and gut microbiome interact to modulate the interface between xenobiotic and intermediary metabolism. We hypothesized that the gut microbiome regulates PCBs-mediated changes in the metabolic fingerprints and hepatic transcriptome. Ninety-day-old female conventional (CV) and germ-free (GF) C57BL/6 mice were orally exposed to the PCB Fox River Mixture (synthetic PCB mixture, 6 or 30 mg/kg) or corn oil (vehicle control, 10 ml/kg), once daily for 3 consecutive days. Organs were collected 24 hours after the final dose. RNA-Seq was conducted on liver, and endogenous aqueous metabolites (amino acids, carbohydrates, and nucleotides) were measured in liver and serum by LC-MS. The primary factor in clustering the transcriptomic and metabolomic signatures within the same exposure was by enterotype. The numbers of PCB-regulated genes were higher in CV than in GF conditions. The prototypical target genes of the major xenobiotic-sensing transcription factors AhR, PXR, and CAR were more readily up-regulated by PCBs in CV than in GF conditions, indicating the effect of PCBs on the hepatic transcriptome act partly through the gut microbiome. Xenobiotic and steroid metabolism pathways were up-regulated, whereas response to incorrect proteins pathway was down-regulated by PCBs in a gut microbiome-dependent manner. At the high PCB dose, NADP and arginine appear to interact with drug-metabolizing enzymes (Cyp1-3 family, DhcR7, and Nqo1), which are highly correlated with <i>Anaerotruncus</i> and <i>Roseburia</i> in CV mice, providing a novel explanation of gut-liver interaction in toxicant exposures. In GF exposure groups, hepatic glucose was down-regulated, whereas fructose 6-phosphate and glucose 6-phosphate were up-regulated, indicating increased glucose utilization potentiated by lack of gut microbiota. Through querying the LINCS L1000 chemical database, Enrichr predicted that therapeutic drugs targeting the anti-inflammatory and ER stress pathways are potential remedies to mitigate PCB toxicity. In conclusion, our findings demonstrate that habitation of the gut microbiota drives PCBs-mediated hepatic responses, possibly due to crosstalk between gut and liver. </span></span></span></p>
Functional multispectral optoacoustic tomography imaging of hepatic steatosis development in mice_image analysis
<p>This dataset contains the HE staining/anti-CD31 staining/ICG fluorescence images and the image quantification data produced for publication "Functional multispectral optoacoustic tomography imaging of hepatic steatosis development in mice"</p>
Functional multispectral optoacoustic tomography imaging of hepatic steatosis development in mice
<p>This dataset contains primary data produced for pulication named 'Functional multispectral optoacoustic tomography imaging of hepatic steatosis development in mice'</p>
Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation
<p>Summary statistics for "Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation" </p><p>Files are organized in the following directory structure:</p><p><strong>G2G/</strong> - Summary statistics of G2G associations (SNPs, HLA, and gene-level analysis). </p><p><strong>HLA/ </strong>- Peptide binding prediction results</p><p><strong>preS1_haplotypes/ - </strong>Resolved intra-host haplotypes of the preS1 binding region. </p><p><strong>DnDs/</strong> - Calculation of intra-host positive selection, within the preS1 binding region. </p><p> </p>
3-(4-Hydroxy-3-methoxyphenyl) propionic acid contributes to improved hepatic lipid metabolism via GPR41
<p class="MsoNormal"><span>3-(4-hydroxy-3-methoxyphenyl) propionic acid (HMPA) is a metabolite produced by the gut microbiota through the conversion of 4-hydroxy-3-methoxycinnamic acid (HMCA), which is a widely distributed hydroxycinnamic acid-derived metabolite found abundantly in plants. Several beneficial effects of HMPA have been suggested, such as antidiabetic properties, anticancer activities, and cognitive function improvement, in animal models and human studies. However, the intricate molecular mechanisms underlying the bioaccessibility and bioavailability profile following HMPA intake and the substantial modulation of metabolic homeostasis by HMPA require further elucidation. In this study, we effectively identified and characterized HMPA-specific GPR41 receptor, with greater affinity than HMCA. The activation of this receptor plays a crucial role in the anti-obesity effects and improvement of hepatic steatosis by stimulating the lipid catabolism pathway. For the improvement of metabolic disorders, our results provide insights into the development of functional foods, including HMPA, and preventive pharmaceuticals targeting GPR41.</span></p>
HIV AND HEPATITIS B AND C IN THE POPULATION INMATES
<pre>Some morbidities reduce work capacity and are strongly associated with the absence of efficient promotion and prevention and monitoring of the disease, such as HIV/AIDS and viral hepatitis. Persons subjected to penalties of deprivation of freedom may be considered to be at high risk for Acquired Immunodeficiency Virus (HIV) infection and viral hepatitis, due to the conditions pportunists found inside prisons for the spread of disease, e.g. overcrowding, promiscuity, unprotected sex in homosexual relationships, sharing razor blades, using illicit drugs, tattooing in unsafe conditions. Research involving the scenario of the population deprived of liberty in Brazilian penitentiaries are still incipient, especially those that seek to monitor diseases such as HIV/AIDS and viral hepatitis, so this project has the main objective of measuring the prevalence of HIV and hepatitis B and C and their associations in prisoners of the prison system of Paraná. This is a cross-sectional epidemiological study, with the application of questionnaires and serological tests for HIV and hepatitis B and C, totaling a sample of 1,225 prisoners. The data presented here are from the individuals tested for HIV - case control.</pre>
Astaxanthin from Haematococcus pluvialis prevents high-fat diet-induced hepatic steatosis and oxidative stress in mice by gut-liver axis modulating properties
<p><strong><span>Scope:</span></strong><span> Evidence is mounting that astaxanthin (ATX), a xanthophyll carotenoid, used as a nutritional supplement to prevent chronic metabolic diseases. The present study aims to identify the potential function of ATX supplementation in preventing steatohepatitis and hepatic oxidative stress in diet-induced obese mice.</span></p> <p><strong><span>Methods and Results:</span></strong><span> In this study, ATX as dose of 0.25%, 0.5% and 0.75% have orally administered to mice along with a high-fat diet (HFD) to investigate the role of ATX in regulating liver lipid metabolism and gut microbiota. The study showed that ATX dose-dependently reduces body weight, lipid droplet formation, hepatic triglycerides and ameliorated hepatic steatosis and oxidative stress. 0.75% ATX altered the levels of 34 lipid metabolites related to hepatic cholesterol and fatty acid metabolism which might be associated with downregulation of lipogenesis-related genes and upregulation of bile acid biosynthesis-related genes. The result also revealed that ATX alleviates HFD-induced gut microbiota dysbiosis by significantly inhibiting the growth of obesity-related <em>Parabacteroides</em> and <em>Desulfovibrio</em> while promoting the growth of <em>Allobaculum</em> and <em>Akkermansia</em>. </span></p> <p><span><strong>Conclusion:</strong> The study results suggested that dietary ATX may prevent the development of hepatic steatosis and oxidative stress with the risk of metabolic disease by gut-liver axis modulating properties.</span></p>
Seasonal weight loss effect in the hepatic fatty acid composition in Australian Merino, Damara and Dorper sheep
<p>Seasonal weight loss (SWL) is one of the major limitations in small ruminant production in drought-prone regions. The study of breeds with higher tolerance to the effects of SWL is particularly important to define breed selection strategies. In this work we evaluated the effect of SWL in the hepatic fatty acids profile in three ovine breeds with different levels of tolerance: the Merino (susceptible to SWL), the Dorper (intermediate tolerant to SWL), and Damara (tolerant to SWL). </p>
Assessment of hepatitis B viral lymphotrophism using deep curation
<p><strong><span>Background</span></strong><span><strong>:</strong> The replicative forms of the hepatitis B virus (HBV) is found in several types of white blood cells within the host defense system. To determine the dimensionality of the extrahepatic manifestation of HBV in host white blood cells, it is important to understand the complete biology of its pathogenesis and lymphotropic nature.</span></p> <p><strong><span>Methods</span></strong><span><strong>: </strong>Deep curation of the literature from the PubMed database pertaining to the HBV manifestation in the human host white blood cells was conducted and then manually filtered to determine the behavioral trend of the virus within the human white blood cells.</span></p> <p><strong><span>Results</span></strong><span><strong>:</strong> The curation of 198 research articles identified 28 genes, 92 proteins, and 20 Peripheral Blood Mononuclear cells involved in HBV pathogenesis, while 20 immune cells were found to be permissive for the viral penetration and replication. The presence of the replicative forms of HBV in the host immune cells led to the further elucidation of 28 genes and 92 proteins that interact with one or more viral genes and proteins.</span></p> <p><strong><span>Conclusions</span></strong><span><strong>:</strong> A multi-dimensional analysis using deep curation identified a possible lymphotropic character of HBV. Moreover, there are certain pathways that could aid in the propagation of viral infection by using immune cells to its advantage. Thus, instead of eliminating HBV, the immune system may contribute to the population expansion of the virus.</span></p>
Ultra-short response-guided Hepatitis C treatment with sofosbuvir and daclatasvir: the SEARCH study HCV sequence data
<p><strong>Background</strong></p> <p>WHO has called for research into predictive factors for selecting persons who could be successfully treated with shorter durations of antiviral therapy for Hepatitis C. We evaluated early virological response as a means of shortening treatment and explored host, viral and pharmacokinetic contributors to treatment outcome.</p> <p class="MsoNormal"><strong><span>Methods</span></strong></p> <p class="MsoNormal"><span>Duration of sofosbuvir and daclatasvir (SOF/DCV)</span> was determined according to <span>day 2 (D2) virologic response</span> for <span>HCV genotype (gt) 1- or 6-infected adults in Vietnam with mild liver disease. Participants received 4 or 8 weeks of treatment according to whether D2 HCV RNA was above or below 500 IU/ml (standard duration is 12 weeks). Primary endpoint was sustained virological response (SVR12). Those failing therapy were retreated with 12 weeks SOF/DCV. Host IFNL4 genotype and viral sequencing was performed at baseline, with repeat viral sequencing if virological rebound was observed. Levels of SOF, its inactive metabolite</span> <span>GS-331007 and DCV were measured on day 0 and 28. </span></p> <p class="MsoNormal"><strong>Findings</strong></p> <p class="MsoNormal"><span>Of 52 adults enrolled, 34 received 4 weeks SOF/DCV, 17 got 8 weeks and one withdrew. SVR12 was achieved in 21/34 (62%) treated for 4 weeks, and 17/17 (100%) treated for 8 weeks. Overall, 38/51 (75%) were cured with first-line treatment </span><span>(mean duration of 37 days). Despite a high prevalence of putative </span>NS5A-inhibitor <span>resistance-associated substitutions (RAS), all first-line treatment failures were cured after retreatment (13/13). We found no evidence treatment failure was associated with host </span><span>IFNL4 genotype, viral</span><span> subtype, baseline RAS or DCV levels. SOF metabolite levels were higher in those failing 4-week therapy.</span></p> <p class="MsoNormal"><strong>Interpretation</strong></p> <p class="MsoNormal">Shortened SOF/DCV therapy with retreatment if needed, reduces DAA use while maintaining high cure rates. D2 virologic response alone does not adequately predict SVR12 with 4 weeks of treatment.</p>
Hepatitis B Virus - Geneious BAM files
<p>BAM files for specimens assembled in Geneious including their genotype specific references.</p>
Data from: Hepatic steatosis induced by nicotine plus Coca-Cola™ is prevented by nicotinamide riboside (NR)
<p><strong>Introduction.</strong> Cigarettes containing nicotine (Nic) are a risk factor for the development of cardiovascular and metabolic diseases. We reported that Nic delivered via injections or e-cigarette vapor led to hepatic steatosis in mice fed with a high-fat diet. High-fructose corn syrup (HFCS) is the main sweetener in sugar-sweetened beverages (SSBs) in the US. Increased consumption of SSBs with HFCS is associated with increased risks of non-alcoholic fatty liver disease (NAFLD). Nicotinamide riboside (NR) increases mitochondrial nicotinamide adenine dinucleotide (NAD<sup>+</sup>) and protects mice against hepatic steatosis. This study evaluated if Nic plus Coca-Cola™ (Coke) with HFCS can cause hepatic steatosis and that can be protected by NR.</p> <p><strong>Methods.</strong> C57BL6 mice received twice daily intraperitoneal (IP) injections of Nic or saline and were given Coke (HFCS), or Coke with sugar, and NR supplementation for 10 weeks.</p> <p><strong>Results.</strong> Our results show that Nic+Coke caused increased caloric intake and induced hepatic steatosis, and the addition of NR prevented these changes. Western blot analysis showed lipogenesis markers were activated (increased cleavage of the sterol regulatory element-binding protein 1 [SREBP1c] and reduction of phospho-Acetyl-CoA Carboxylase [p-ACC]) in the Nic+Coke compared to the Sal+Water group. The hepatic detrimental effects of Nic+Coke were mediated by decreased NAD<sup>+</sup> signaling, increased oxidative stress, and mitochondrial damage. NR reduced oxidative stress and prevented mitochondrial damage by restoring protein levels of Sirtuin1 (Sirt1) and peroxisome proliferator-activated receptor coactivator 1-alpha (PGC1a) signaling.</p> <p><strong>Discussion.</strong> We conclude that Nic+Coke has an additive effect on producing hepatic steatosis, and NR is protective. This study suggests concern for the development of NAFLD in subjects who consume nicotine and drink SSBs with HFCS.</p>
Data from: Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression
<p>Constitutive Androstane Receptor (CAR, <em>Nr1i3</em>), a liver nuclear receptor and xenobiotic sensor, induces drug, steroid and lipid metabolizing enzymes, stimulates liver hypertrophy and hyperplasia, and ultimately, hepatocellular carcinogenesis. The mechanisms linking early CAR responses to later disease development are poorly understood. Here we show that exposure of CD-1 mice to TCPOBOP, a halogenated xenochemical and selective CAR agonist ligand, induces pericentral steatosis marked by hepatic accumulation of cholesterol and neutral lipid, and elevated circulating alanine aminotransferase, indicating hepatocyte damage. TCPOBOP-induced steatosis was weaker in the pericentral region but stronger in the periportal region in females compared to males. Early (1-day) TCPOBOP transcriptional responses were enriched for CAR-bound primary response genes, and for lipogenesis and xenobiotic metabolism and oxidative stress protection pathways; late (2-wk) TCPOBOP responses included many CAR binding-independent secondary response genes, with enrichment for macrophage activation, immune response and cytokine and reactive oxygen species production. Late upstream regulators specific to TCPOBOP-exposed male liver were linked to pro-inflammatory responses and hepatocellular carcinoma progression. TCPOBOP administered weekly to male mice using a high corn oil vehicle activated carbohydrate-responsive transcription factor (MLXIPL)-regulated target genes, dysregulated mitochondrial respiratory and translation regulatory pathways, and induced more advanced liver pathology. Overall, TCPOBOP exposure recapitulates histological and gene expression changes characteristic of emerging steatotic liver disease, including secondary gene responses in liver non-parenchymal cells indicative of transition to a more advanced disease state. Upstream regulators of both the early and late TCPOBOP response genes include novel biomarkers for foreign chemical-induced metabolic dysfunction-associated steatotic liver disease.</p>
Original NGS dataset from publication "Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center".
<p>Original hepatitis C virus hypervariable region 1 NGS sequences in fastq format from patients analyzed in the study "Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center". </p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.